ary prophylaxis of venous thromboembolism (VTE) in men with prostate cancer in Sweden. Solutions: This population-based record-linkage cohort study employed data from the National Prostate Cancer Register, the Prescribed Drug Registry as well as the Patient Registry in Sweden. We identified males having a initially VTE among 2013 and 2017 and described the type and duration of outpatient anticoagulation they received. Final results: Amongst 1413 integrated guys, 96 began outpatient anticoagulant therapy within 4 weeks just after VTE diagnosis. Practically two-thirds (64 ) had been prescribed parenteral anticoagulation, 31 a NOAC and 20 a VKA (men could receive 1 sort of anticoagulant). Over the study period, use of parental anticoagulation declined from 83 to 53 , VKA use declined from 45 to 4 , and NOAC use improved from 5 to 51 . Males received their initial prescription within 1 days immediately after their recorded VTE (median of two days). The median duration of use was 7 months (interquartile variety [IQR] 33). A fifth of males have been dispensed three months anticoagulation, over half (57 ) six months’ anticoagulation, and a quarter 1 year of anticoagulation. Duration was longer for pulmonary embolism (median 8 months, IQR 55) than for deep vein thrombosis (median 6 months, IQR 3). Conclusions: Males with prostate cancer and VTE in Sweden had been dispensed an average of 7 months’ anticoagulation; however, a wide range of therapy durations had been observed reflecting the individualised strategy to treating VTE in these heterogeneous patients.PB1123|The usage of DOACS in Catheter Connected Thrombosis in Cancer U. Faruqi; G. Bahra; P.-L. Luo; Z. Mahir; A. Danaee Guys and St Thomas’ NHS Foundation Trust, London, United kingdom Background: Currently, there is no consensus around the optimal management of catheter connected upper extremity deep vein thrombosis826 of|ERK1 Activator manufacturer ABSTRACT(UEDVT) in cancer sufferers. There is certainly rising proof for DOACs in cancer related thrombosis (CAT) but there’s a paucity of data for the use of these agents in UEDVT. Aims: To describe a single centre expertise around the use of DOAC in cancer sufferers with catheter connected UEDVT. Procedures: Retrospective cohort study on the management of UEDVT in cancer individuals in between 2019 and 2020 at Guys and St Thomas’ Hospital London. Data was collected by reviewing electronic case notes and thrombosis confirmed on ultrasound doppler reports. Final results: There have been 53 patients with UEDVT: 48 (90.five ) PICC, three (5.6 ) IL-5 Antagonist web portacath and two (three.7 ) cannula connected thrombosis. The PICC thromboses had been sub-analysed (Table 1). PICC lines have been in situ for a mean of 48.eight days (inter quartile range 41.7 days) till thrombosis improvement. All individuals were initiated on low molecular weight heparin (LMWH) till critique in CAT clinic when anticoagulation was converted to DOAC in 20 sufferers (43.7 ) after risk assessment. Two individuals (9.five ) reported bleeding on DOACs. 1 minor bleeding and one clinically relevant non-major bleeding event with epistaxis requiring attendance to hospital. Bleeding was defined as per the ISTH criteria. There had been no recurrent line thromboses on anticoagulation with DOACs or LMWH. 3 sufferers developed recurrent thromboses on DOACS (one superficial vein, two PE) and two patients on LMWH (one particular superficial vein, a single PE). 13 (27 ) patients continued DOAC prophylaxis following 3 months treatment dose with no recurrent line thrombosis. TABLE 1 Baseline demographics of individuals presenting with PICC connected UEDVTConclusions: Even though this can be a sm